These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24878976)

  • 1. Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture.
    Drobny M; Pullmann R; Odalos I; Skerenova M; Saniova B
    Neuro Endocrinol Lett; 2014; 35(2):123-8. PubMed ID: 24878976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
    García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
    García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.
    Goettsch WG; Heintjes EM; Kastelein JJ; Rabelink TJ; Johansson S; Herings RM
    Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):435-43. PubMed ID: 16761304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statin therapy and muscle disorders].
    Abel T; Fehér J
    Orv Hetil; 2009 Feb; 150(6):261-3. PubMed ID: 19179258
    [No Abstract]   [Full Text] [Related]  

  • 6. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.
    McAfee AT; Ming EE; Seeger JD; Quinn SG; Ng EW; Danielson JD; Cutone JA; Fox JC; Walker AM
    Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):444-53. PubMed ID: 16761308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
    Davidson MH
    Expert Opin Drug Saf; 2004 Nov; 3(6):547-57. PubMed ID: 15500414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.
    Golightly LK; Barber GR; Barron MA; Page RL
    Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
    Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
    Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
    García Rodríguez LA; Herings R; Johansson S
    Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.
    Zuccaro P; Mombelli G; Calabresi L; Baldassarre D; Palmi I; Sirtori CR
    Pharmacol Res; 2007 Apr; 55(4):310-7. PubMed ID: 17289397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment.
    van Staa TP; Carr DF; O'Meara H; McCann G; Pirmohamed M
    Br J Clin Pharmacol; 2014 Sep; 78(3):649-59. PubMed ID: 24602118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
    S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing statin-induced muscle toxicity in a lipid clinic.
    Blaier O; Lishner M; Elis A
    J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myopathy caused by a combination rosuvastatin and fenofibrate.
    Dedhia V; Munsi SC
    J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin.
    Evangelista T; Ferro J; Pereira P; de Carvalho M
    Neuromuscul Disord; 2009 Jan; 19(1):66-8. PubMed ID: 19084404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Glueck CJ; Rawal B; Khan NA; Yeramaneni S; Goldenberg N; Wang P
    Metabolism; 2009 Feb; 58(2):233-8. PubMed ID: 19154957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.